论文部分内容阅读
目的:探讨依达拉奉联合肝素钠治疗进展性脑梗塞的临床疗效以及安全性。方法:将100例进展性脑梗塞患者随机分为对照组和治疗组,每组50例。在个体化常规治疗的基础上,治疗组给予依达拉奉联合肝素钠,对照组应用低分子肝素钙,疗程结束,评价其疗效,并对结果进行分析。结果:治疗组总有效率为74.0%,对照组总有效率为48%。治疗组疗效明显好于对照组,两组比较差异有统计学意义(P<0.05)。结论:依达拉奉联合肝素钠能有效阻止病情进展,改善进展性脑梗塞患者的神经功能。
Objective: To investigate the clinical efficacy and safety of edaravone combined with heparin in the treatment of advanced cerebral infarction. Methods: 100 patients with progressive cerebral infarction were randomly divided into control group and treatment group, 50 cases in each group. On the basis of individualized routine treatment, the treatment group was given edaravone combined with heparin sodium, while the control group was given low molecular weight heparin calcium. The course of treatment was over, the curative effect was evaluated, and the result was analyzed. Results: The total effective rate was 74.0% in the treatment group and 48% in the control group. The treatment group was significantly better than the control group, the difference between the two groups was statistically significant (P <0.05). Conclusion: Edaravone combined with heparin sodium can effectively prevent the progression of the disease and improve the neurological function in patients with progressive cerebral infarction.